Jiangsu Hengrui Pharmaceuticals Co.,Ltd Fundamental Analysis
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Fundamental Analysis
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK) shows moderate financial fundamentals with a PE ratio of 39.89, profit margin of 24.95%, and ROE of 13.28%. The company generates $35.5B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 75.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 1276.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent1276.HK demonstrates superior asset utilization.
Valuation Score
Weak1276.HK trades at a premium to fair value.
Growth Score
Moderate1276.HK shows steady but slowing expansion.
Financial Health Score
Excellent1276.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate1276.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 1276.HK Expensive or Cheap?
P/E Ratio
1276.HK trades at 39.89 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1276.HK's PEG of 2.10 indicates potential overvaluation.
Price to Book
The market values Jiangsu Hengrui Pharmaceuticals Co.,Ltd at 5.10 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 40.18 times EBITDA. This signals the market has high growth expectations.
How Well Does 1276.HK Make Money?
Net Profit Margin
For every $100 in sales, Jiangsu Hengrui Pharmaceuticals Co.,Ltd keeps $24.95 as profit after all expenses.
Operating Margin
Core operations generate 26.54 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.28 in profit for every $100 of shareholder equity.
ROA
Jiangsu Hengrui Pharmaceuticals Co.,Ltd generates $11.03 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Jiangsu Hengrui Pharmaceuticals Co.,Ltd generates strong operating cash flow of $12.51B, reflecting robust business health.
Free Cash Flow
Jiangsu Hengrui Pharmaceuticals Co.,Ltd generates strong free cash flow of $9.26B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.39 in free cash annually.
FCF Yield
1276.HK converts 2.56% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
39.89
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.10
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.10
vs 25 benchmark
P/S Ratio
Price to sales ratio
10.18
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
9.23
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How 1276.HK Stacks Against Its Sector Peers
| Metric | 1276.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 39.89 | 29.60 | Worse (Expensive) |
| ROE | 13.28% | 418.00% | Weak |
| Net Margin | 24.95% | -11442.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.78 | Strong (Low Leverage) |
| Current Ratio | 9.23 | 5.13 | Strong Liquidity |
| ROA | 11.03% | -74.00% (disorted) | Strong |
1276.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Jiangsu Hengrui Pharmaceuticals Co.,Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation